Syneron Bio Announces Strategic Collaboration with AstraZeneca
Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leaderAstraZenecato develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases.Under this collaboration,AstraZeneca will gain access toSyneron Bio's innovative Synova™ platform, an intelligentand high-throughput macrocyclic peptide drug research and development platform, designed to support the […]